<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Metastatic disease</z:e> is the principle cause of <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In that context, the most significant indicator of overall survival and therapeutic response to adjuvant chemotherapy is the presence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumor</z:e> cells in regional lymph nodes </plain></SENT>
<SENT sid="2" pm="."><plain>Although histopathologic analysis of lymph nodes is central to <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> staging paradigms, its prognostic and predictive value is limited </plain></SENT>
<SENT sid="3" pm="."><plain>Indeed, about 30% of patients with histopathology-negative lymph nodes (pN0) die from <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e>, reflected by microscopic <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> that are overlooked by standard techniques </plain></SENT>
<SENT sid="4" pm="."><plain>These unrecognized <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells are especially important when considering racial disparities in outcomes in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients, where blacks with lymph node-negative disease have the largest discrepancies in outcomes, with more than 40% excess mortality compared to Caucasian patients </plain></SENT>
<SENT sid="5" pm="."><plain>However, the significance of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in regional lymph nodes remains uncertain, and approximately 50% of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients with nodal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> detected by histopathology remain free of <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Accurate identification of occult <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in regional lymph nodes, and defining their value as prognostic markers of recurrence risk and predictive markers of response to adjuvant chemotherapy remains one challenge in the management of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="7" pm="."><plain>Guanylyl cyclase C (GUCY2C), a receptor which is expressed primarily in intestinal cells normally, but is universally over-expressed by <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells, has been validated to detect prognostically significant occult <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> using quantitative RT-PCR (RT-qPCR) </plain></SENT>
<SENT sid="8" pm="."><plain>Biomarker validation was achieved through a prospective, multicenter, blinded clinical trial </plain></SENT>
<SENT sid="9" pm="."><plain>In that trial, occult <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden estimated across <z:hpo ids='HP_0000001'>all</z:hpo> regional lymph nodes by GUCY2C RT-qPCR predicted clinical outcomes, identifying node-negative patients with a low (near zero) risk, and those with &gt;80% risk, of developing disease recurrence </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, there was disproportionately higher occult <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden in black, compared to white, patients which contributes to racial disparities in outcomes in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The diagnostic paradigm quantifying occult <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden using GUCY2C qRT-PCR is positioned to reduce racial disparities in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> mortality </plain></SENT>
</text></document>